Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ILK | Q13418 | 8/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31428522 | 0.89 | DYRK1A (0.47) | NPC1LIPGDYRK1AKMT2ASMN1; SMN2 | |
| SCHEMBL31428948 | 0.83 | LMNA (0.49) | NPC1LMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL17038141 | 0.80 | RAB9A (0.59) | NPC1LMNAKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL24975786 | 0.77 | RAB9A (0.44) | NPC1LMNAKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL11173803 | 0.75 | MAPT (0.56) | NPC1LMNADYRK1ASMN1; SMN2ALDH1A1 | |
| SCHEMBL15949950 | 0.74 | GRM2 (0.46) | DYRK1AL3MBTL1MAOB | |
| SCHEMBL31429045 | 0.74 | ALDH1A1 (0.41) | NPC1LIPGKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL31428905 | 0.74 | KMT2A (0.40) | DYRK1AKMT2AALDH1A1MAPT | |
| SCHEMBL28217860 | 0.74 | ALDH1A1 (0.53) | NPC1LMNAKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL31428550 | 0.72 | HSD17B10 (0.57) | NPC1LMNADYRK1AKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2025-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | BRAF, RAF1, NRAS | NPC1 3237/4885LMNA 4297/4885LIPG 4235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.